

## Arbeiten aus der Klinik 2015

Anzahl Publikationen: 170  
Davon IF-Arbeiten: 127  
Summe IF: 556.456

1. **Adorjan K, Koller G, Pogarell O**  
Die kritische Phase nach dem Entzug.  
MMW Fortschr Med 2015; 157: 53-55. IF -
2. **Aichmüller C, Soyka M**  
Müdigkeit bei Suchterkrankungen.  
Swiss Medical Forum 2015; 15: 391-394. IF -
3. **Antal A, Keeser D, Priori A, Padberg F, Nitsche MA**  
Conceptual and Procedural Shortcomings of the Systematic Review "Evidence That Transcranial Direct Current Stimulation (tDCS) Generates Little-to-no Reliable Neurophysiologic Effect Beyond MEP Amplitude Modulation in Healthy Human Subjects: A Systematic Review" by Horvath and Co-workers.  
Brain Stimul 2015; 8: 846-9. IF 4.793
4. **Aust S, Palm U, Padberg F, Bajbouj M**  
Transkranielle Gleichstromstimulation bei depressiven Störungen.  
Nervenarzt 2015; 86: 1492-99. IF 0.806
5. **Ayache SS, Créange A, Farhat WH, Zouari HG, Lesage C, Palm U, Abdellaoui M, Lefaucheur J-P**  
Cortical excitability changes over time in progressive multiple sclerosis.  
Functional Neurology 2015; 30: 1-8. IF -
6. **Ayache SS, Palm U, Chalah MA, Nguyen R, Farhat WH, Créange A, Lefaucheur JP**  
Orienting network dysfunction in progressive multiple sclerosis.  
J Neurol Sci 2015; 351: 206-207. IF 2.126
7. **Badowska DM, Reich-Erkelenz D, Schmitt A, Falkai P**  
Pathways to personalized treatment strategies for depressive disorders.  
Eur Arch Psychiatry Clin Neurosci 2015; 265: 1-3. IF 4.113
8. **Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller H-J; WFSBP Task Force on Treatment Guidelines for Unipolar Depression Disorders.**  
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015.

World J Biol Psychiatry 2015; 16: 76-95. IF 4.159

9. **Bendfeldt K, Smieskova R, Koutsouleris N, Klöppel S, Schmidt A, Walter A, Harrisberger F, Wrege J, Simon A, Taschler B, Nichols T, Riecher-Rössler A, Lang UE, Radue EW, Borgwardt S**  
Classifying individuals at high-risk for psychosis based on functional brain activity during working memory processing.  
Neuroimage Clin 2015; 9: 555-63. IF 3.857
10. **Benetti S, Pettersson-Yeo W, Allen P, Catani M, Williams S, Barsaglini A, Kambeitz-Illankovic LM, McGuire P, Mechelli A**  
Auditory verbal hallucinations and brain dysconnectivity in the perisylvian language network: a multimodal investigation.  
Schizophr Bull 2015; 41: 192-200. IF 7.757
11. **Bhattacharyya S, Atakan Z, Martin-Santos R, Crippa JA, Kambeitz J, Malhi S, Giampietro V, Williams S, Brammer M, Rubia K, Collier DA, McGuire PK**  
Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis.  
Eur Neuropsychopharmacol 2015; 25: 26-37. IF 4.409
12. **Bhugra D, Ventriglio A, Kuzman MR, Ikkos G, Hermans MH, Falkai P, Fiorillo A, Musalek M, Hoschl C, Dales J, Beezhold J, Rössler W, Racetovic G, Gaebel W**  
EPA guidance on the role and responsibilities of psychiatrists.  
Eur Psychiatry 2015; 30: 417-22. IF 3.912
13. **Born C, de la Fontaine L, Winter B, Müller N, Schaub A, Früstück C, Schüle C, Voderholzer U, Cuntz U, Falkai P, Meisenzahl E**  
First results of a refeeding program in a psychiatric intensive care unit for patients with extreme anorexia nervosa.  
BMC Psychiatry 2015; 15: 57. IF 2.576
14. **Brendel M, Pogarell O, Xiong G, Delker A, Bartenstein P, Rominger A; Alzheimer's Disease Neuroimaging Initiative.**  
Depressive symptoms accelerate cognitive decline in amyloid-positive MCI patients.  
Eur J Nucl Med Mol Imaging 2015; 42: 716-24. IF 5.537
15. **Bridler R, Häberle A, Müller ST, Cattapan K, Grohmann R, Toto S, Kasper S, Greil W**  
Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: A comparison with other psychiatric disorders.  
Eur Neuropsychopharmacol 2015; 25: 764-772. IF 4.409
16. **Bruch J, Kurz C, Vasiljevic A, Nicolino M, Arzberger T, Höglinger GU**  
Early neurodegeneration in the brain of a child without functional PKR-like endoplasmic reticulum kinase.  
J Neuropathol Exp Neurol 2015; 74: 850-7. IF 3.432
17. **Brunnauer A, Buschert V, Fric M, Distler G, Sander K, Segmiller F, Zwanzger P, Laux G**

Driving performance and psychomotor function in depressed patients treated with agomelatine or venlafaxine.  
*Pharmacopsychiatry* 2015; 48: 65-71. IF 1.474

18. **Buch S, Stickel F, Trépo E, Way M, Herrmann A, Nischalke HD, Brosch M, Rosendahl J, Berg T, Ridinger M, Rietschel M, McQuillin A, Frank J, Kiefer F, Schreiber S, Lieb W, Soyka M, Semmo N, Aigner E, Datz C, Schmelz R, Brückner S, Zeissig S, Stephan AM, Wodarz N, Devière J, Clumeck N, Sarrazin C, Lammert F, Gustot T, Deltenre P, Völzke H, Lerch MM, Mayerle J, Eyer F, Schafmayer C, Cichon S, Nöthen MM, Nothnagel M, Ellinghaus D, Huse K, Franke A, Zopf S, Hellerbrand C, Moreno C, Franchimont D, Morgan MY, Hampe J**  
A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis.  
*Nat Genet* 2015; 47: 1443-8. IF 31.616
  
19. **Cassoli JS, Guest PC, Malchow B, Schmitt A, Falkai P, Martins-de-Souza D**  
Disturbed macro-connectivity in schizophrenia linked to oligodendrocyte dysfunction: from structural findings to molecules.  
*npj Schizophrenia* 2015; 1: 15034. IF -
  
20. **Cimander KF, Poehlke T, Soyka M**  
Erfahrungen mit der Umstellung von Methadon-Razemat auf Levomethadon im Therapiealltag.  
*Suchtmed* 2015; 17: 7-19. IF -
  
21. **Cross-Villasana F, Finke K, Hennig-Fast K, Kilian B, Wiegand I, Müller HJ, Möller H-J, Töllner T**  
The speed of visual attention and motor-response decisions in adult attention-deficit/hyperactivity disorder.  
*Biol Psychiatry* 2015; 78: 107-15. IF 11.212
  
22. **Dabbert D, Zimmermann J, Toto S, Grohmann R**  
Ich-dystone Suizidgedanken nach Absetzen einer dreitägigen Sertralin-Gabe.  
*Psychopharmakotherapie* 2015; 22: 212-3. IF -
  
23. **Dehning S, Burger MB, Krause D, Jobst A, Yundina E, Müller N, Meyer S, Zill P, Buchheim A**  
Tourette syndrome is associated with insecure attachment and higher aggression.  
*Int J Neurosci* 2015; 125: 521-5. IF 1.717
  
24. **Diedrich A, Voderholzer U**  
Obsessive-compulsive personality disorder: a current review.  
*Curr Psychiatry Rep* 2015; 17: 2. IF 2.858
  
25. **Dieterich DC, Rossner MJ**  
Dissecting the regional diversity of glial cells by applying -omic technologies.  
*e-neuroforum* 2015; 6: 63-68. IF -

26. **Durrenberger PF, Fernando FS, Kashefi SN, Bonnert TP, Seilhean D, Nait-Oumesmar B, Schmitt A, Gebicke-Haerter PJ, Falkai P, Grünblatt E, Palkovits M, Arzberger T, Kretschmar H, Dexter DT, Reynolds R**  
Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study.  
J Neural Transm (Vienna) 2015; 122: 1055-68. IF 2.587
27. **Edbauer D, Arzberger T**  
Brain banks still yield high interest rates.  
J Neural Transm (Vienna) 2015; 122: 935-6. IF 2.587
28. **Falkai P**  
Der Mensch im Mittelpunkt – Chancen der individualisierten Psychiatrie und Psychotherapie.  
Fortschr Neurol Psychiatr 2015; 83: 605. IF 0.803
29. **Falkai P**  
Nachruf auf Prof. Dr. Kurt Heinrich.  
Fortschr Neurol Psychiatr 2015; 83: 592. IF 0.803
30. **Falkai P, Hasan A**  
Freud und Leid mit den Leitlinien.  
Der Neurologe und Psychiater 2015; 16: 3-4 IF -
31. **Falkai P, Hasan A, Koutsouleris N**  
Chancen der individualisierten Psychiatrie und Psychotherapie am Beispiel schizophrener Psychosen.  
Die Psychiatrie 2015; 12: 255-260. IF -
32. **Falkai P, Rossner MJ, Schulze TG, Hasan A, Brzòzka MM, Malchow B, Honer WG, Schmitt A**  
Kraepelin revisited: schizophrenia from degeneration to failed regeneration.  
Mol Psychiatry 2015; 20: 671-6. IF 13.314
33. **Falkai P, Schmitt A**  
Erythropoietin as an innovative add-on therapy for depression.  
Biol Psychiatry 2015; 78: 222-3. IF 11.212
34. **Falkai P, Schmitt A**  
Risikofaktoren für Depression und Angststörungen und der Einsatz von Lichttherapie.  
Fortschr Neurol Psychiatr 2015; 83: 313. IF 0.803
35. **Fichter MM**  
Anorektische und bulimische Essstörungen.  
In: Berger M (Hrsg). Psychische Erkrankungen, Klinik und Therapie.  
Elsevier, München, 2015, S. 547-563.
36. **Fichter M**  
Epidemiologie der Essstörungen.  
In: Herpertz S, de Zwann M, Zipfel S (Hrsg).

Handbuch Essstörungen und Adipositas.  
Springer, Berlin Heidelberg 2015, S. 45-55.

37. **Fichter MM, Quadflieg N, Gierk B, Voderholzer U, Heuser J**  
The Munich Eating and Feeding Disorder Questionnaire (Munich ED-Quest)  
DSM-5/ICD-10: Validity, reliability, sensitivity to change and norms.  
Eur Eat Disorders Rev 2015; 23: 229-240. IF 2.912
38. **Fountoulakis KN, Gonda X, Baghai TC, Baldwin DS, Bauer M, Blier P, Gattaz W, Hasler G, Möller HJ, Tandon R, Vieta E, Kasper S**  
Report of the WPA section of pharmacopsychiatry on the relationship of  
antiepileptic drugs with suicidality in epilepsy.  
Int J Psychiatry Clin Pract 2015; 19: 158-67. IF 1.278
39. **Franke AG, Soyka M**  
Pharmakologisches Neuroenhancement aus Sicht der Suchtmedizin.  
Fortschr Neurol Psychiatr 2015; 83: 83-90. IF 0.803
40. **Franke AG, Soyka M**  
Psychopharmakotherapie vs. Cognitive Neuroenhancement.  
Suchtmed 2015; 17: 219-223. IF -
41. **Gaebel W, Falkai P, Sartorius N, Zielasek J**  
Leitlinien weltweit bei psychiatrischen Erkrankungen.  
Die Psychiatrie 2015; 12: 3-4. IF -
42. **Gaebel W, Zielasek J, Falkai P**  
Psychotic Disorders in ICD-11.  
Die Psychiatrie 2015; 12: 71-76. IF -
43. **Gade K, Malzahn D, Anderson-Schmid H, Strohmaier J, Meier S, Frank J, Falkai PG, Rietschel M, Schulze TG**  
Functional outcome in major psychiatric disorders and associated clinical and  
psychosocial variables: a potential cross-diagnostic phenotype for further  
genetic investigations?  
World J Biol Psychiatry 2015; 16: 237-48. IF 4.159
44. **Giese A, Arzberger T**  
In memoriam: Hans A. Kretschmar (1953-2014).  
J Neural Transm (Vienna) 2015; 122: 934-5. IF 2.587
45. **Großimlinghaus I, Falkai P, Gaebel W, Hasan A, Jänner M, Janssen B, Reich-Erkelenz D, Grüber L, Böttcher V, Wobrock T, Ziesalek J; LVR-Klinikverbund**  
Erhebung von Qualitätsindikatoren anhand von Routinedaten. Darstellung  
eines Machbarkeitstests in 10 Fachkliniken für Psychiatrie und  
Psychotherapie.  
Nervenarzt 2015; 86: 1393-99. IF 0.806
46. **Grüber L, Falkai P, Hasan A**  
Depression bei Schizophrenie.  
Fortschr Neurol Psychiatr 2015; 83: 238-46. IF 0.803

47. **Gürkov R, Berman A, Dietrich O, Flatz W, Jerin C, Krause E, Keeser D, Ertl-Wagner B**  
MR volumetric assessment of endolymphatic hydrops.  
*Eur Radiol* 2015; 25: 585-95. IF 3.640
48. **Guest PC, Iwata K, Kato TA, Steiner J, Schmitt A, Turck CW, Martins-de-Souza D**  
MK-801 treatment affects glycolysis in oligodendrocytes more than in astrocytes and neuronal cells: insights for schizophrenia.  
*Front Cell Neurosci* 2015; 12: 180. IF 4.609
49. **Haas I, Nitsche MA, Grohmann R, Rütther E, Degner D**  
Parästhesien und Gangunsicherheit bei sensomotorischer Polyneuropathie unter Mirtazapin.  
*Psychopharmakotherapie* 2015; 22: 256-9. IF -
50. **Hasan A, Brinkmann C, Strube W, Palm U, Malchow B, Rothwell JC, Falkai P, Wobrock T**  
Investigations of motor-cortex cortical plasticity following facilitatory and inhibitory transcranial theta-burst stimulation in schizophrenia: a proof-of-concept study.  
*J Psychiatr Res* 2015; 61: 196-204. IF 4.465
51. **Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Thibaut F, Möller H-J, WFSBP Task Force on Treatment Guidelines for Schizophrenia.**  
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, suicidality, substance use disorders and pregnancy and lactation.  
*World J Biol Psychiatry* 2015; 16: 142-70. IF 4.159
52. **Hasan A, Wobrock T, Großimlinghaus I, Zielasek J, Janssen B, Reich-Erkelenz D, Kopp I, Gaebel W, Falkai P**  
Die Aktualisierung der DGPPN S3-Leitlinie Schizophrenie – aktueller Stand.  
*Die Psychiatrie* 2015; 12: 19-27. IF -
53. **Hasan A, Wobrock T, Palm U, Strube W, Padberg F, Falkai P, Fallgatter A, Plewnia C**  
Hirnstimulationsverfahren zur Behandlung schizophrener Psychosen.  
*Nervenarzt* 2015; 86: 1481-91. IF 0.806
54. **Hasan A, Wolff-Menzler-C, Pfeiffer S, Falkai P, Weidinger E, Jobst A, Hoell I, Malchow B, Yeganeh-Doost P, Strube W, Quast S, Müller N, Wobrock T**  
Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: a bicentric randomized controlled pilot study.  
*Eur Arch Psychiatry Clin Neurosci* 2015; 265: 589-600. IF 4.113
55. **Heilbronner U, Hinrichs H, Heinze H-J, Zaehle**  
Caffeine differentially alters cortical hemodynamic activity during working memory: a near infrared spectroscopy study.  
*BMC Res Notes* 2015; 8: 520. IF -

56. **Heilbronner U, Malzahn D, Strohmaier J, Maier S, Frank J, Treutlein J, Mühleisen TW, Forstner AJ, Witt SH, Cichon S, Falkai P, Nöthen MM, Rietschel M, Schulze TG**  
A common risk variant in CACNA1C supports a sex-dependent effect on longitudinal functional recovery from episodes of schizophrenia-spectrum but not bipolar disorder.  
*Eur Neuropsychopharmacol* 2015; 25: 2262-70. IF 4.409
57. **Hennig-Fast K, Michl P, Müller J, Niedermeier N, Coates U, Müller N, Engel RR, Möller H-J, Reiser M, Meindl T**  
Obsessive-compulsive disorder – a question of conscience? An fMRI study of behavioral and neurofunctional correlates of shame and guilt.  
*J Psychiatr Res* 2015; 68: 354-62 IF 4.465
58. **Herold S, Kumar P, Wichert SP, Kretschmar B, Bähr M, Rossner MJ, Hein K**  
Neurodegeneration in Autoimmune Optic Neuritis Is Associated with Altered APP Cleavage in Neurons and Up-Regulation of p53.  
*PLoS One* 2015; 10: 0138852. IF 3.057
59. **Holl AK, Grohmann R, Leitmaier M, Painold A, Mörkl S, Toto S, Kasper S**  
Pharmacotherapy of anxiety disorders in German-speaking countries: current status and changes between 1994 and 2011.  
*Eur Arch Psychiatry Clin Neurosci* 2015; 265: 199-208. IF 4.113
60. **Ihl R, Bunevicius R, Frölich L, Winblad B, Schneider LS, Dubois B, Burns A, Thibaut F, Kasper S, Möller H-J; WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Dementia**  
World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care.  
*Int J Psychiatry Clin Pract* 2015; 19: 2-7. IF 1.278
61. **Jobst A, Sabass L, Palagyi A, Bauriedl-Schmidt C, Mauer MC, Sarubin N, Buchheim A, Renneberg B, Falkai P, Zill P, Padberg F**  
Effects of social exclusion on emotions and oxytocin and cortisol levels in patients with chronic depression.  
*J Psychiatr Res* 2015; 60: 170-77. IF 4.465
62. **Juraeva D, Treutlein J, Scholz H, Frank J, Degenhardt F, Cichon S, Ridinger M, Mattheisen M, Witt SH, Lang M, Sommer WH, Hoffmann P, Herms S, Wodarz N, Soyka M, Zill P, Maier W, Jünger E, Gaebel W, Dahmen N, Scherbaum N, Schmäler C, Steffens M, Lucae S, Ising M, Smolka MN, Zimmermann US, Müller-Myhsok B, Nöthen MM, Mann K, Kiefer F, Spanagel R, Brors B, Rietschel M.**  
XRCC5 as a risk gene for alcohol dependence: evidence from a genome-wide gene-set-based analysis and follow-up studies in Drosophila and humans.  
*Neuropsychopharmacol* 2015; 40: 361-71. IF 6.399

63. **Kambeitz JP, Howes OD**  
The serotonin transporter in depression: Meta-analysis of in vivo and post mortem findings and implications for understanding and treating depression. *J Affect Disord* 2015; 186: 358-366. IF 3.570
64. **Kambeitz J, Kambeitz-Ilankovic L, Leucht S, Wood S, Davatzikos C, Malchow B, Falkai P, Koutsouleris N**  
Detecting neuroimaging biomarkers for schizophrenia: a meta-analysis of multivariate pattern recognition studies. *Neuropsychopharmacology* 2015; 40: 1742-51. IF 6.399
65. **Karch S, Keeser D, Hümmer S, Paolini M, Kirsch V, Karali T, Kupka M, Rauchmann BS, Chrobok A, Blautzik J, Koller G, Ertl-Wagner B, Pogarell O**  
Modulation of craving related brain responses using real-time fMRI in patients with alcohol use disorder. *PLoS One* 2015; e0133034. IF 3.057
66. **Karch S, Pogarell O**  
Neurobiologie bei Zwangsstörung. *Psychologie in Österreich* 2015; 1: 7-16. IF –
67. **Kasparbauer AM, Rujescu D, Riedel M, Pogarell O, Costa A, Meindl T, la Fougère C, Ettinger U**  
Methylphenidate effects on brain activity as a function of SLC6A3 genotype and striatal dopamine transporter availability. *Neuropsychopharmacology* 2015; 30: 736-45. IF 6.399
68. **Kerkemeyer L, Mostardt S, Biermann J, Wasem J, Neumann A, Walendzik A, Jahn R, Bartels C, Falkai P, Brannath W, Breunig-Lyriti V, Mester B, Timm J, Wobrock T**  
Evaluation of an integrated care program for schizophrenia: concept and study design. *Eur Arch Psychiatry Clin Neurosci* 2015; 265: 155-62. IF 4.113
69. **Klioueva NM, Rademaker MC, Dexter DT, Al-Sarraj S, Seilhean D, Streichenberger N, Schmitz P, Bell JE, Ironside JW, Arzberger T, Huitinga I**  
BrainNet Europe's Code of Conduct for brain banking. *J Neural Transm (Vienna)* 2015; 122: 937-40. IF 2.587
70. **Kittel-Schneider S, Wobrock T, Scherk H, Schneider-Axmann T, Trost S, Zilles D, Wolf C, Schmitt A, Malchow B, Hasan A, Backens M, Reith W, Falkai P, Gruber O, Reif A**  
Influence of DGKH variants on amygdala volume in patients with bipolar affective disorder and schizophrenia. *Eur Arch Psychiatry Clin Neurosci* 2015; 265: 127-36. IF 4.113
71. **Köhler S, Wiethoff K, Ricken R, Stamm T, Baghai TC, Fisher R, Seemüller F, Brieger P, Cordes J, Malevani J, Laux G, Hauth I, Möller H-J, Zeiler J, Heinz A, Bauer M, Adli M**  
Characteristics and differences in treatment outcome of inpatients with



chronic vs. episodic major depressive disorders.  
*J Affect Disord* 2015; 173: 126-33. IF 3.570

72. **Koerner N, Schmidt P, Soyka M**  
Decision making and impulsiveness in abstinent alcohol-dependent people and healthy individuals: a neuropsychological examination.  
*Substance Abuse Treatment, Prevention, and Policy* 2015; 10: 24.  
IF 1.713
73. **Koerte IK, Lin AP, Muehlmann M, Merugumala S, Liao H, Starr T, Kaufmann D, Mayinger M, Steffinger D, Fisch B, Karch S, Heinen F, Ertl-Wagner B, Reiser M, Stern RA, Zafonte R, Shenton ME**  
Altered neurochemistry in former professional soccer players without a history of concussion.  
*J Neurotrauma* 2015; 32: 1287-93. IF 4.377
74. **Koller G, Pogarell O**  
Suchterkrankungen im Diagnostischen und Statistischen Manual Psychischer Störungen DSM-5.  
*Die Psychiatrie* 2015; 12: 110-117. IF -
75. **Koller G, Preuss U, Lü O, Soyka M, Pogarell O**  
Alcohol-dependent subjects show different personality traits compared with subjects with multiple substance dependence: preliminary data.  
*J Addict Med* 2015; 9: 257-260. IF 2.065
76. **Koutsouleris N, Meisenzahl EM, Borgwardt S, Riecher-Rössler A, Frodl T, Kambeitz J, Köhler Y, Falkai P, Möller H-J, Reiser M, Davatzikos C**  
Individualized differential diagnosis of schizophrenia and mood disorders using neuroanatomical biomarkers.  
*Brain* 2015; 138: 2059-073. IF 10.103
77. **Koutsouleris N, Riecher-Rössler A, Meisenzahl EM, Smieskova R, Studerus E, Kambeitz-Illankovic L, von Saldern C, Cabral C, Reiser M, Falkai P, Borgwardt S**  
Detecting the psychosis prodrome across high-risk populations using neuroanatomical biomarkers.  
*Schizophr Bull* 2015; 41: 471-82. IF 7.757
78. **Kulla P, Schlegl S, Külz AK, Förstner U, Warschburger P, Voderholzer U**  
Funktionalitäten von Zwangsstörungen – Entwicklung und Validierung eines Fragebogens (FFZ).  
*Psychother Psychosom Med Psychol.* 2015; 65: 213-222. IF 1.018
79. **Laoutidis ZG, Konstantinidis A, Grohmann R, Luckhaus C, Mobascher J, Cordes J**  
Reversible amisulpride-induced elevation of creatine kinase (CK): a case series from the German AMSP Pharmacovigilance project.  
*Pharmacopsychiatry* 2015; 48: 178-181. IF 1.474
80. **Laqua C, Zill P, Koller G, Preuss U, Soyka M**  
Assoziation des MAOA-uVNTR-Polymorphismus mit antisozialem Verhalten

bei alkoholabhängigen Männern.  
Fortschr Neurol Psychiatr 2015; 83: 162-169. IF 0.803

81. **Levkovitz Y, Isserles M, Padberg F, Lisanby SH, Bystritsky A, Xia G, Tendler A, Daskalakis ZJ, Winston JL, Dannon P, Hafez HM, Reti IM, Morales OG, Schlaepfer TE, Hollander E, Berman JA, Husain MM, Sofer U, Stein A, Adler S, Deutsch L, Deutsch F, Roth Y, George MS, Zangen A**  
Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial.  
World Psychiatry 2015; 14: 64-73. IF 20.205
82. **Liu J, Zhu MW, Arzberger T, Wang LN**  
Frontotemporal lobar degeneration with accumulation of argyrophillic grains and lewy bodies: a clinicopathological report.  
J Alzheimers Dis 2015; 48: 55-8. IF 3.920
83. **Malchow B, Hasan A, Meyer K, Schneider-Axmann T, Radenbach KE, Gruber O, Reith W, McIntosh AM, Schmitt A, Falkai P, Wobrock T**  
Family load impacts orbitofrontal volume in first-episode schizophrenia.  
Psychiatry Res 2015; 232: 130-33. IF 2.466
84. **Malchow B, Keller K, Hasan A, Dörfler S, Schneider-Axmann T, Hillmer-Vogel U, Honer WG, Schulz TG, Wobrock T, Schmitt A, Falkai P**  
Effects of endurance training combined with cognitive remediation on everyday functioning, symptoms and cognition in multiepisode schizophrenia patients.  
Schizophr Bull 2015; 41: 847-58. IF 7.757
85. **Malchow B, Strocka S, Frank F, Bernstein H-G, Steiner J, Schneider-Axmann T, Hasan A, Reich-Erkelenz D, Schmitz C, Bogerts B, Falkai P, Schmitt A**  
Stereological investigation of the posterior hippocampus in affective disorders.  
J Neural Transm 2015; 122: 1019-33. IF 2.587
86. **Meyronet D, Dorey A, Massoma P, Rey C, Alix E, Silva K, Perrin C, Quadrio I, Perret-Liaudet A, Streichenberger N, Thomasset N, Honnorat J, Arzberger T, Kretschmar H**  
The workflow from post-mortem human brain sampling to cell microdissection: a Brain Net Europe study.  
J Neural Transm (Vienna) 2015; 122:975-91. IF 2.587
87. **Möller H-J, Bandelow B, Bauer M, Hampel H, Herpertz SC, Soyka M, Barnikol UB, Lista S, Severus E, Maier W**  
DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences - part 1: general aspects and paradigmatic discussion of depressive disorders.  
Eur Arch Psychiatry Clin Neurosci 2015; 265: 5-18. IF 4.113
88. **Möller H-J, Bandelow B, Bauer M, Hampel H, Herpertz SC, Soyka M, Barnikol UB, Lista S, Severus E, Maier W**  
DSM-5 reviewed from different angles: goal attainment, rationality, use of

evidence, consequence - part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders.

Eur Arch Psychiatry Clin Neurosci 2015; 265: 87-106. IF 4.113

89. **Möller H-J, Czobor P**  
Pharmacological treatment of negative symptoms in schizophrenia.  
Eur Arch Psychiatry Clin Neurosci 2015; 265: 567-78. IF 4.113
90. **Möller H-J, Laux G, Deister A**  
Duale Reihe Psychiatrie, Psychosomatik und Psychotherapie.  
Thieme, Stuttgart, 2015.
91. **Möller-Leimkühler AM**  
Gut getarnt ist halb gewonnen? Depression bei Männern.  
In: Franz M, Karger A (Hrsg) Angstbeißer, Trauerkloß, Zappelphilipp?  
Seelische Gesundheit bei Männern und Jungen.  
Vandenhoeck & Ruprecht, 2015, S. 88-104.
92. **Mondino M, Brunelin J, Palm U, Brunoni AR, Poulet E, Fecteau S**  
Transcranial direct current stimulation for the treatment of refractory symptoms of schizophrenia. Current evidence and future directions.  
Curr Pharmaceutical Design 2015; 21: 3373-3383. IF 3.052
93. **Musil R**  
Weight gain as a consequence of treatment with antipsychotics.  
Die Psychiatrie 2015; 12: 262-268. IF -
94. **Musil R, Obermeier M, Russ P, Hamerle M**  
Weight gain and antipsychotics: a drug safety review.  
Expert Opin Drug Saf 2015; 14: 73-96. IF 2.896
95. **Nedopil N, Taylor P, Gunn J**  
Forensic psychiatry in Europe: the perspective of the Ghent Group.  
Int J Psychiatry Clin Pract 2015; 19: 80-3. IF 1.278
96. **Norman C, Wolff J, Hochlehnert A, Klein JP, Hohagen F, Lieb K, Deckert J, Falkai P, Berger M, Herpertz SC**  
Aufwand und Finanzierung leitliniengerechter, psychotherapeutischer Behandlung im Krankenhaus.  
Nervenarzt 2015; 86: 534-41. IF 0.806
97. **Padberg F, Sabaß L, Dewald-Kaufmann J, Jobst A**  
Psychotherapie der chronischen Depression.  
Nervenheilkunde 2015; 34: 880-887. IF -
98. **Paolini M, Keeser D, Ingrisich M, Werner N, Kindermann N, Reiser M, Blautzik J**  
Resting-state networks in healthy adult subjects: a comparison between a 32-element and an 8-element phased array head coil at 3.0 Tesla.  
Acta Radiol 2015; 56: 605-13. IF 2.009

99. **Palm U**  
„Electricität“ – keine Wunder, aber beachtliche Wirkung.  
Nervenarzt 2015; 86: 635-636. IF 0.806
100. **Palm U, Leitner B, Strube W, Hasan A, Padberg F**  
Safety of repeated twice-daily 30 minutes of 2 mA tDCS in depressed patients.  
Int Neuropsychiatric Dis J 2015; 4: 168-171. IF –
101. **Palm U, Padberg F, Remi J**  
Transcranial direct current stimulation (tDCS) in a patient with PRES and bipolar depression. Transkranielle Gleichstromstimulation (tDCS) bei PRES und bipolarer Störung.  
Fortschr Neurol Psychiatr 2015; 83: e11-e13. IF 0.803
102. **Palm U, Strube W, Bunse T, Bauer I, Dunkel G, Hasan A, Pfeiffer A, Padberg F**  
Transkranielle Gleichstromstimulation in der Psychiatrie. Update 2015.  
Nervenheilkunde 2015; 34: 1016-1025. IF -
103. **Popp J, Wolfsgruber S, Heuser I, Peters O, Hüll M, Schröder J, Möller H-J, Lewczuk P, Schneider A, Jahn H, Luckhaus C, Perceczky R, Frölich L, Wagner M, Maier W, Wiltfang J, Kornhuber J, Jessen F**  
Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.  
Neurobiol Aging 2015; 36: 601-7. IF 5.153
104. **Preuss UW, Koller G, Samochowiec A, Zill P, Samochowiec J, Kucharska-Mazur J, Wong J, Soyka M**  
Serotonin and dopamine candidate gene variants and alcohol- and non-alcohol-related aggression.  
Alcohol Alcoholism 2015; 50: 690-99. IF 2.724
105. **Quadflieg N, Fichter M**  
Verlauf der Bulimia nervosa und Bing-Eating-Störung.  
In: Herpertz S, de Zwaan M, Zipfel S (Hrsg).  
Handbuch Essstörungen und Adipositas. Springer, Berlin Heidelberg, 2015, S. 63-69.
106. **Ramos-Miguel A, Hercher C, Beasley C, Barr AM, Bayer TA, Falkai P, Leurgans SE, Schneider JA, Bennett DA, Honer WG**  
Loss of Munc18-1 long splice variant in GABAergic terminals is associated with cognitive decline and increased risk of dementia in a community sample.  
Mol Neurodegener 2015; 10: 65. IF 6.510
107. **Reich-Erkelenz D, Schmitt A, Falkai P**  
Genetic and environmental risk factors in neurodevelopmental disorders.  
Eur Arch Psychiatry Clin Neurosci 2015; 265: 445-447. IF 4.113
108. **Reich-Erkelenz D, Schmitt A, Falkai P**  
Psychiatrists' self-stigma, the DGPPN guideline for psychosocial interventions, and contemporary treatment strategies.  
Eur Arch Psychiatry Clin Neurosci 2015; 265: 171-72. IF 4.113

109. **Reich-Erkelenz D, Schmitt A, Falkai P**  
Unravelling basic mechanisms in addiction and neuropsychiatric disorders.  
*Eur Arch Psychiatry Clin Neurosci* 2015; 265: 633-5. IF 4.113
110. **Rice SM, Fallon BJ, Aucote HM, Möller-Leimkühler AM, Treeby MS, Amminger GP**  
Longitudinal sex differences of externalising and internalising depression symptom trajectories: Implications for assessment of depression in men from an online study.  
*Int J Soc Psychiatry* 2015; 61: 236-40. IF 1.098
111. **Rominger A, Cumming P, Brendel M, Xiong G, Zach C, Karch S, Tatsch K, Bartenstein P, la Fougère C, Koch W, Pogarell O**  
Altered serotonin and dopamine transporter availabilities in brain of depressed patients upon treatment with escitalopram: A [<sup>123</sup>I]β-CIT SPECT study.  
*Eur Neuropsychopharmacol* 2015; 25: 873-81. IF 4.409
112. **Rüther T, Wissen F, Linhardt A, Aichert DS, Pogarell O, de Vries Hein**  
Electronic cigarettes – attitudes and use in Germany.  
*Nicotine & Tobacco Research* 2015. IF 3.811
113. **Saia-Cereda VM, Cassoli JS, Schmitt A, Falkai P, Nascimento JM, Martins-de-Souza D**  
Proteomics of the corpus callosum unravel pivotal players in the dysfunction of cell signaling, structure, and myelination in schizophrenia brains.  
*Eur Arch Psychiatry Clin Neurosci* 2015; 265: 601-12. IF 4.113
114. **Salize HJ, Voß E, Werner A, Falkai P, Hauth I**  
Behandlungspfade in der Versorgung von Patienten mit Schizophrenie und Depression.  
*Nervenarzt* 2015; 86: 1358-70. IF 0.806
115. **Samara MT, Leucht C, Leeflang MM, Anghelescu IG, Chung YC, Crespo-Facorro B, Elkis H, Hatta K, Giegling I, Kane JM, Kayo M, Lambert M, Lin CH, Möller H-J, Pelayo-Terán JM, Riedel M, Rujescu D, Schimmelmann BG, Serretti A, Correll CU, Leucht S**  
Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review.  
*Am J Psychiatry* 2015; 172:617-29. IF 13.505
116. **Sarubin N, Gutt D, Giegling I, Bühner M, Hilbert S, Krähenmann O, Wolf M, Jobst A, Sabaß L, Rujescu D, Falkai P, Padberg F**  
Erste Analyse der psychometrischen Eigenschaften und Struktur der deutschsprachigen 10- und 25-Item Version der Connor-Davidson Resilience Scale (CD-RISC).  
*Zeitschrift für Gesundheitspsychologie* 2015; 23: 112-122. IF -
117. **Sarubin N, Wolf M, Giegling I, Hilbert S, Naumann F, Gutt D, Jobst A, Sabaß L, Falkai P, Rujescu D, Bühner M, Padberg F**  
Neuroticism and extraversion as mediators between positive/negative life events and resilience.  
*Personality and Individual Differences* 2015; 82: 193-198. IF 1.946

118. **Scarr E, Millan MJ, Bahn S, Bertolino A, Turck CW, Kapur S, Möller H-J, Dean B**  
Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the 2013 CINP Think Tank.  
*Int J Neuropsychopharmacol* 2015; 18: pyv042. IF 4.333
119. **Schennach R, Riedel M, Obermeier M, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rütger E, Klingberg S, Gastpar M, Möller H-J**  
What are depressive symptoms in acutely ill patients with schizophrenia spectrum disorder?  
*Eur Psychiatry* 2015; 30: 43-50. IF 3.912
120. **Schlegl S, Bürger C, Schmidt L, Herbst N, Voderholzer U**  
The potential of technology-based psychological interventions for anorexia and bulimia nervosa: a systematic review and recommendations for future research.  
*J Med Internet Res* 2015; 17: e85. IF 4.532
121. **Schludi MH, May S, Grässer FA, Rentzsch K, Kremmer E, Küpper C, Klopstock T; German Consortium for Frontotemporal Lobar Degeneration; Bavarian Brain Banking Alliance, Arzberger T, Edbauer D**  
Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing.  
*Acta Neuropathol* 2015; 130: 537-55. IF 11.360
122. **Schludi MH, May S, Grässer FA, Rentzsch K, Kremmer E, Küpper C, Klopstock T; German Consortium for Frontotemporal Lobar Degeneration; Bavarian Brain Banking Alliance, Arzberger T, Edbauer D**  
Erratum to: Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing.  
*Acta Neuropathol* 2015; 130: 557-58.
123. **Schmitt A, Falkai P**  
Classification and neurobiological concepts of mania, bipolar disorder and major depression.  
*Eur Arch Psychiatry Clin Neurosci* 2015; 265: 271-72. IF 4.113
124. **Schmitt A, Falkai P**  
DGPPN guideline on anxiety disorders and cognitive dysfunction in the elderly or patients with multiple sclerosis.  
*Eur Arch Psychiatry Clin Neurosci* 2015; 265: 361-2. IF 4.113
125. **Schmitt A, Falkai P**  
Negative symptoms and therapy strategies in schizophrenia.  
*Eur Arch Psychiatry Clin Neurosci* 2015; 265: 541-2. IF 4.113

126. **Schmitt A, Falkai P**  
Schizophrenia spectrum and related neuropathology.  
Eur Arch Psychiatry Clin Neurosci 2015; 265: 85-6. IF 4.113
127. **Schmitt A, Malchow B, Keeser D, Falkai P, Hasan A**  
Neurobiologie der Schizophrenie. Aktuelle Befunde von der Struktur zu den Molekülen.  
Nervenarzt 2015; 86: 324-331. IF 0.806
128. **Schnell C, Shahmoradi A, Wichert SP, Mayerl S, Hagos Y, Heuer H, Rossner MJ, Hülsmann S**  
The multispecific thyroid hormone transporter OATP1C1 mediates cell-specific sulforhodamine 101-labeling of hippocampal astrocytes.  
Brain Struct Funct 2015; 220: 193-203. IF 5.811
129. **Shahmoradi A, Radyushkin K, Rossner MJ**  
Enhanced memory consolidation in mice lacking the circadian modulators Sharp1 and -2 caused by elevated Igf2 signaling in the cortex.  
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3582-9. IF 9.423
130. **Sharma K, Schmitt S, Bergner CG, Tyanova S, Kannaiyan N, Manrique-Hoyos N, Kongi K, Cantuti L, Hanisch UK, Philips MA, Rossner MJ, Mann M, Simons M**  
Cell type- and brain region-resolved mouse brain proteome.  
Nat Neurosci 2015; 18: 1819-31. IF 16.724
131. **Soyka M**  
Affektive und Angststörungen und komorbide Suchterkrankungen.  
In: Walter M, Gouzoulis-Mayfrank E (Hrsg.)  
Psychische Störungen und Suchterkrankungen.  
Kohlhammer, Stuttgart 2015, S. 88-104.
132. **Soyka M**  
Alkohol als komorbide Störung bei Drogenabhängigkeit.  
HIV&more 2015; 4: 18-19. IF -
133. **Soyka M**  
Alcohol-related disorders.  
In: Wrigth JD (ed). International Eyclopedia of the Social & Behavioral Sciences. Elsevier, Oxford, 2015, Vol. 1, pp 507-512.
134. **Soyka M**  
Alcohol use disorders in opioid maintenance therapy: prevalence, clinical correlates and treatment.  
Eur Addict Res 2015; 21: 78-87. IF 2.367
135. **Soyka M**  
Benzodiazepine. Abhängigkeit von Hypnotika und Tranquilizern.  
DNP Der Neurologe & Psychiater 2015; 16: 42-46. IF -
136. **Soyka M**  
Buprenorphine–naloxone buccal soluble film for the treatment of opioid

dependence: current update.  
Expert Opin Drug Deliv 2015; 12: 339-47. IF 5.434

137. **Soyka M**  
Comorbidity of anxiety disorders and substance use.  
In: Dom G, Moggi (ed).  
Co-occurring Addictive and Psychiatric Disorders.  
Springer, Berlin Heidelberg 2015. S 149-16.
138. **Soyka M**  
Neuroenhancement – die Illusion vom chemischen Glück.  
Neurologie & Psychiatrie 2015; 4: 41-43. IF -
139. **Soyka M**  
New developments in the management of opioid dependence: focus on  
sublingual buprenorphine-naloxone.  
Substance Abuse and Rehabilitation 2015; 6: 1-14. IF -
140. **Soyka M**  
Pharmacotherapy in dual disorders.  
In: Dom G, Moggi (ed).  
Co-occurring Addictive and Psychiatric Disorders.  
Springer, Berlin Heidelberg 2015. S. 279-306.
141. **Soyka M**  
Psychiatrische Begutachtung von Ärzten und Apothekern zu  
approbationsrechtlichen Fragen.  
In: Venzlaff U, Foerster K (Hrsg.)  
Psychiatrische Begutachtung. Ein praktisches Handbuch für Ärzte und  
Juristen.  
Urban & Fischer, München, 2015, S. 725-729.
142. **Soyka M**  
Therapie der Alkoholabhängigkeit.  
CME 2015; 12: 57-63. IF -
143. **Soyka M, Batra A**  
Benzodiazepinabhängigkeit (ICD-10 F.13.2)  
In: Voderholzer U, Hohagen F (Hrsg.)  
Therapie psychischer Erkrankungen. State of the Art.  
Elsevier, München, 2015, S. 51-58.
144. **Soyka M, Baumgärtner G**  
Schweregradeinteilung für Suchterkrankungen im neuen DSM-5.  
Swiss Arch Neurology Psychiatry 2015; 166: 45-50. IF -
145. **Soyka M, Fischer W**  
No evidence for development of tolerance after repeated use of propofol for  
electroconvulsive therapy.  
Pharmacopsychiatry 2015; 48: 7-10. IF 1.474
146. **Soyka M, Grunze H**  
Pharmacotherapy of Dual Disorders.



In: Dom G, Moggi F (eds). Co-occurring Addictive and Psychiatric Disorders. Springer, Berlin Heidelberg, 2015, S. 279-306.

147. **Soyka M, Lieb M**  
Recent developments in pharmacotherapy of alcoholism.  
Pharmacopsychiatry 2015; 48: 123-35. IF 1.474
148. **Soyka M, Zill P, Koller G, Samochowiec A, Grzywacz A, Preuss UW**  
Val158Met COMT polymorphism and risk of aggression in alcohol dependence.  
Addict Biol 2015; 20: 197-204. IF 4.547
149. **Spindelegger C, Papageorgiou K, Grohmann R, Engel R, Greil W, Konstantinidis A, Agelink MW, Bleich S, Ruether E, Toto S, Kasper**  
Cardiovascular adverse reactions during antidepressant treatment: a drug surveillance report of German-speaking countries between 1993 and 2010.  
Int J Neuropsychopharmacol 2015; 18: pyu080. IF 4.333
150. **Stegmayer K, Usher J, Trost S, Henseler I, Tost H, Rietschel M, Falkai P, Gruber O**  
Disturbed cortico-amygdalar functional connectivity as pathophysiological correlate of working memory deficits in bipolar affective disorder.  
Eur Arch Psychiatry Clin Neurosci 2015; 265: 303-11. IF 4.113
151. **Strobel S, Grünblatt E, Riederer P, Heinsen H, Arzberger T, Al-Sarraj S, Troakes C, Ferrer I, Monoranu CM**  
Changes in the expression of genes related to neuroinflammation over the course of sporadic Alzheimer's disease progression: CX3CL1, TREM2, and PPAR $\gamma$ .  
J Neural Transm (Vienna) 2015; 122: 1069-76. IF 2.587
152. **Strube W, Bunse T, Malchow B, Hasan A**  
Efficacy and interindividual variability in motor-cortex plasticity following anodal tDCS and paired-associative stimulation.  
Neural Plast 2015; 530423. IF 3.568
153. **Strube W, Bunse T, Malchow B, Hasan A**  
Corrigendum to „Efficacy and interindividual variability in motor-cortex plasticity following anodal tDCS and paired-associative stimulation.  
Neural Plast 2015; 903265.
154. **Strube W, Bunse T, Nitsche MA, Wobrock T, Aborowa R, Misewitsch K, Herrmann M, Falkai P, Hasan A**  
Smoking restores impaired LTD-like plasticity in schizophrenia: a transcranial direct current stimulation study.  
Neuropsychopharmacol 2015; 40: 822-30. IF 6.399
155. **Strube W, Nitsche MA, Wobrock T, Bunse T, Rein B, Herrmann M, Schmitt A, Nieratschker V, Witt SH, Rietschel M, Falkai P, Hasan A**  
BDNF-Val66Met-polymorphism impact on cortical plasticity in schizophrenia patients: a proof-of-concept study.  
Int J Neuropsychopharmacol 2015; 18: pyu040. IF 4.333

156. **Thal DR, von Arnim CA, Griffin WS, Mrak RE, Walker L, Attems J, Arzberger T**  
Frontotemporal lobar degeneration FTLD-tau: preclinical lesions, vascular, and Alzheimer-related co-pathologies.  
J Neural Transm (Vienna) 2015; 122: 1007-18. IF 2.587
157. **Thibaut F, Boutros NN, Jarema M, Oranje B, Hasan A, Daskalakis ZJ, Wichniak A, Schmitt A, Riederer P, Falkai P; WFSBP Task Force on Biological Markers**  
Consensus paper of the WFSBP Task Force on Biological Markers: criteria for biomarkers and endophenotypes of schizophrenia part I: Neurophysiology.  
World J Biol Psychiatry 2015; 16: 280-90. IF 4.159
158. **Tordesillas-Gutierrez D, Koutsouleris N, Roiz-Santiañez R, Meisenzahl E, Ayesa-Arriola R, Marco de Lucas E, Soriano-Mas C, Suarez-Pinilla P, Crespo-Facorro B**  
Grey matter volume differences in non-affective psychosis and the effects of age of onset on grey matter volumes: a voxelwise study.  
Schizophr Res 2015; 164: 74-82. IF 4.453
159. **Tschirdewahn J, Vignaud P, Pfeiffer A, Nolden J, Padberg F, Palm U**  
Neue Therapieoption bei Depression: die transkranielle Gleichstromstimulation.  
MMW Fortschritte der Medizin 2015; 157: 46-49. IF -
160. **Van Eijk L, Groot ER, van Spronsen M, Maas YJ, Keeser D, Pogarell O, Engelbregt HJ**  
Testing Van Gool's Hypothesis: a method to predict side effects of cholinesterase inhibitors in patients with cellular degenerative and vascular dementia.  
Advances Geriatrics 2015; 270657. IF -
161. **Voderholzer U, Schlegl S, Diedrich A, Külz AK, Thiel N, Hertenstein E, Schwartz C, Rufer M, Herbst N, Nissen C, Hillebrand T, Osen B, Stengler K, Jelinek L, Moritz S**  
Versorgung Zwangserkrankter mit kognitiver Verhaltenstherapie als Behandlungsmethode erster Wahl.  
Verhaltenstherapie 2015; 25: 183-190. IF 0.622
162. **Wessels H, Wagner M, Frommann I, Berning J, Pützfeld V, Janssen B, Bottlender R, Maurer K, Möller H-J, Gaebel W, Häfner H, Maier W, Klosterkötter J, Bechdolf A**  
Neuropsychologische Funktionen als Prädiktoren des Therapieerfolgs von psychoedukativer, kognitiv verhaltenstherapeutischer Therapie bei Personen mit erhöhtem Psychoserisiko.  
Psychiatr Prax 2015; 42: 313-9. IF 1.612

163. **Whitfield JB, Rahman K, Haber PS, Day CP, Masson S, Daly AK, Cordell HJ, Mueller S, Seitz HK, Liangpunsakul S, Westerhold C, Liang T, Lumeng L, Foroud T, Nalpas B, Mathurin P, Stickel F, Soyka M, Botwin GJ, Morgan TR, Seht D, GenomALC Consortium**  
Brief Report: Genetics of alcoholic cirrhosis –genom ALC multinational study.  
*Alcohol Clin Exp Res* 2015; 39: 836-42. IF 2.829
164. **Wigand M, Kubicki M, Clemm von Hohenberg C, Leicht G, Karch S, Eckbo R, Pelavin PE, Hawley K, Rujescu D, Bouix S, Shenton ME, Mulert C**  
Auditory verbal hallucinations and the interhemispheric auditory pathway in chronic schizophrenia.  
*World J Biol Psychiatry* 2015; 16: 31-44. IF 4.159
165. **Wobrock T, Guse B, Cordes J, Wölwer W, Winterer G, Gaebel W, Langguth B, Landgrebe M, Eichhammer P, Frank E, Hajak G, Ohmann C, Verde PE, Rietschel M, Ahmed R, Honer WG, Malchow B, Schneider-Axmann T, Falkai P, Hasan A**  
Left prefrontal high-frequency repetitive transcranial magnetic stimulation for the treatment of schizophrenia with predominant negative symptoms: a sham-controlled, randomized multicenter trial.  
*Biol Psychiatry* 2015; 77: 979-988. IF 11.212
166. **Yousefi BH, Manook A, Grimmer T, Arzberger T, von Reutern B, Henriksen G, Drzezga A, Förster S, Schwaiger M, Wester HJ**  
Characterization and first human investigation of FIBT, a novel fluorinated A $\beta$  plaque neuroimaging PET radioligand.  
*ACS Chem Neurosci* 2015; 6: 428-37. IF 4.348
167. **Yu D, Mathews CA, Scharf JM, Neale BM, Davis LK, Gamazon ER, Derks EM, Evans P, Edlund CK, Crane J, Fagerness JA, Osiecki L, Gallagher P, Gerber G, Haddad S, Illmann C, McGrath LM, Mayerfeld C, Arepalli S, Barlassina C, Barr CL, Bellodi L, Benarroch F, Berrió GB, Bienvenu OJ, Black DW, Bloch MH, Brentani H, Bruun RD, Budman CL, Camarena B, Campbell DD, Cappi C, Silgado JC, Cavallini MC, Chavira DA, Chouinard S, Cook EH, Cookson MR, Coric V, Cullen B, Cusi D, Delorme R, Denys D, Dion Y, Eapen V, Egberts K, Falkai P, Fernandez T, Fournier E, Garrido H, Geller D, Gilbert DL, Girard SL, Grabe HJ, Grados MA, Greenberg BD, Gross-Tsur V, Grünblatt E, Hardy J, Heiman GA, Hemmings SM, Herrera LD, Hezel DM, Hoekstra PJ, Jankovic J, Kennedy JL, King RA, Konkashbaev AI, Kremeyer B, Kurlan R, Lanzagorta N, Leboyer M, Leckman JF, Lennertz L, Liu C, Lochner C, Lowe TL, Lupoli S, Macciardi F, Maier W, Manunta P, Marconi M, McCracken JT, Mesa Restrepo SC, Moessner R, Moorjani P, Morgan J, Muller H, Murphy DL, Naarden AL, Nurmi E, Ochoa WC, Ophoff RA, Pakstis AJ, Pato MT, Pato CN, Piacentini J, Pittenger C, Pollak Y, Rauch SL, Renner T, Reus VI, Richter MA, Riddle MA, Robertson MM, Romero R, Rosário MC, Rosenberg D, Ruhrmann S, Sabatti C, Salvi E,**

**Sampaio AS, Samuels J, Sandor P, Service SK, Sheppard B, Singer HS, Smit JH, Stein DJ, Strengman E, Tischfield JA, Turiel M, Valencia Duarte AV, Vallada H, Veenstra-VanderWeele J, Walitza S, Wang Y, Weale M, Weiss R, Wendland JR, Westenberg HG, Shugart YY, Hounie AG, Miguel EC, Nicolini H, Wagner M, Ruiz-Linares A, Cath DC, McMahon W, Posthuma D, Oostra BA, Nestadt G, Rouleau GA, Purcell S, Jenike MA, Heutink P, Hanna GL, Conti DV, Arnold PD, Freimer NB, Stewart SE, Knowles JA, Cox NJ, Pauls DL**

Cross-disorder genome-wide analyses suggest a complex genetic relationship between Tourette`s syndrome and OCD.

*Am J Psychiatry* 2015; 172: 82-93. IF 13.505

168. **Zhang T, Koutsouleris N, Meisenzahl E, Davatzikos C**  
Heterogeneity of structural brain changes in subtypes of schizophrenia revealed using magnetic resonance imaging pattern analysis.  
*Schizophr Bull* 2015; 41: 74-84. IF 7.757
169. **Zohar J, Stahl S, Möller H-J, Blier P, Kupfer D, Yamawaki S, Uchida H, Spedding M, Goodwin GM, Nutt D**  
A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature.  
*Eur Neuropsychopharmacol* 2015; 25: 2318-25. IF 4.409
170. **Zhu MW, Liu J, Arzberger T, Wang LN, Wang ZF**  
Typical or atypical progressive supranuclear palsy: a comparative clinicopathologic study of three Chinese cases.  
*Int J Clin Exp Pathol* 2015; 8: 867-74. IF 1.581